252 related articles for article (PubMed ID: 26743342)
21. Incidence and Outcomes of Bacterial Bloodstream Infections during Acute Graft-versus-Host Disease Involving the Gastrointestinal Tract after Hematopoietic Cell Transplantation.
Petersen J; Lindner C; Hakki M
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1648-1653. PubMed ID: 31002988
[TBL] [Abstract][Full Text] [Related]
22. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
[TBL] [Abstract][Full Text] [Related]
24. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
El-Jawahri A; Li S; Antin JH; Spitzer TR; Armand PA; Koreth J; Nikiforow S; Ballen KK; Ho VT; Alyea EP; Dey BR; McAfee SL; Glotzbecker BE; Soiffer RJ; Cutler CS; Chen YB
Biol Blood Marrow Transplant; 2016 May; 22(5):910-8. PubMed ID: 26748160
[TBL] [Abstract][Full Text] [Related]
25. Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Hosoba S; Waller EK; Shenvi N; Graiser M; Easley KA; Al-Kadhimi Z; Andoh A; Antun AG; Barclay S; Josephson CD; Koff JL; Khoury HJ; Langston AA; Zimring JC; Roback JD; Giver CR
Biol Blood Marrow Transplant; 2018 May; 24(5):973-982. PubMed ID: 29307717
[TBL] [Abstract][Full Text] [Related]
26. Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation.
Gonçalves MV; Yamamoto M; Kimura EY; Colturato VA; de Souza MP; Mauad M; Ikoma MV; Novis Y; Rocha V; Ginani VC; Wanderley de Oliveira Felix OM; Seber A; Kerbauy FR; Hamerschlak N; Orfao A; Rodrigues CA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1223-9. PubMed ID: 25792371
[TBL] [Abstract][Full Text] [Related]
27. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia.
Gratwohl A; Brand R; Apperley J; Biezen Av Av; Bandini G; Devergie A; Schattenberg A; Frassoni F; Guglielmi C; Iacobelli S; Michallet M; Kolb HJ; Ruutu T; Niederwieser D;
Blood; 2002 Dec; 100(12):3877-86. PubMed ID: 12433695
[TBL] [Abstract][Full Text] [Related]
28. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
29. Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: A meta-analysis.
Yan Z; Chen X; Wang H; Chen Y; Chen L; Wu P; Wang W
Medicine (Baltimore); 2018 Jul; 97(27):e10310. PubMed ID: 29979374
[TBL] [Abstract][Full Text] [Related]
30. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
31. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival.
Finazzi MC; Boschini C; Craddock C; Rambaldi A; Ward J; Malladi RK
Br J Haematol; 2020 Feb; 188(4):550-559. PubMed ID: 31713861
[TBL] [Abstract][Full Text] [Related]
33. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
Cho BS; Lee SE; Song HH; Lee JH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1136-43. PubMed ID: 22261380
[TBL] [Abstract][Full Text] [Related]
34. Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children.
Ke P; Bao X; Zhou J; Zhu Q; Zhuang J; Hu X; Liu Y; Wu D; Xue S; Zhang X; Ma X
Acta Haematol; 2019; 142(4):217-223. PubMed ID: 31597154
[TBL] [Abstract][Full Text] [Related]
35. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study.
Gallardo D; de la Cámara R; Nieto JB; Espigado I; Iriondo A; Jiménez-Velasco A; Vallejo C; Martín C; Caballero D; Brunet S; Serrano D; Solano C; Ribera JM; de la Rubia J; Carreras E
Haematologica; 2009 Sep; 94(9):1282-8. PubMed ID: 19734420
[TBL] [Abstract][Full Text] [Related]
36. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Mohty M; Bay JO; Faucher C; Choufi B; Bilger K; Tournilhac O; Vey N; Stoppa AM; Coso D; Chabannon C; Viens P; Maraninchi D; Blaise D
Blood; 2003 Jul; 102(2):470-6. PubMed ID: 12649133
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
38. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
39. Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis.
Ma L; Han X; Jiang S; Meng Q; Zhang L; Bao H
Hematology; 2020 Dec; 25(1):356-365. PubMed ID: 33054609
[TBL] [Abstract][Full Text] [Related]
40. Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.
Ponce DM; Gonzales A; Lubin M; Castro-Malaspina H; Giralt S; Goldberg JD; Hanash AM; Jakubowski A; Jenq R; Papadopoulos EB; Perales MA; van den Brink MR; Young JW; Boulad F; O'Reilly RJ; Prockop S; Small TN; Scaradavou A; Kernan NA; Stevens CE; Barker JN
Biol Blood Marrow Transplant; 2013 Jun; 19(6):904-11. PubMed ID: 23416854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
